Selcia Ltd. has entered into a drug discovery collaboration with Cantab Anti-Infectives to accelerate Cantab’s development program for improved antibiotics for multidrug-resistant Gram-negative bacterial infections based on the polymyxin nucleus.   Polymyxins have become an important ‘last resort’ therapy for certain MDR Gram-negative infections, but have complex pharmacokinetics and dose-limiting toxicities. Polymyxins are the only effective antibiotic to act specifically on Gram-negative bacte...